MedTrace Logo

CPOD Patient's Tolerance of Intermittent Exercise With Inter-exercise Recovery Under Normoxic Hypoxia

NCT07072975 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-10-01

No results posted yet for this study

Summary

Exercise retraining improves the prognosis and quality of life of patients with chronic lung or circulatory diseases. However, exercise intolerance may be caused by excessive ventilatory. Exposure to oxygen-replete air reduces this ventilatory overload, improves sleep and enhances responses to exercise. This study examine the impact of the acute manipulation of oxygen availability during inter-exercise recovery period of an intermittent cycling exercise on perceptual responses.

this randomized, controlled, study include adult patient with COPD. On separate days, 50 patients with COPD completed four sets of 4-min at 85% of VO2peak intercept by 3-min of passive recovery in two randomized between-sets recovery conditions. Rating exertion perception, gaz exchanges, heart rate, sleep quality and nocturnal heart rate variability were assessed.

Hypoxic exposure during inter-repetition recovery phases would reduce the ventilatory load during exercise. What's more, patients would not be forced to perform the sporting gesture in a restricted space or wearing a mask, limiting dyspnea and the perceived difficulty of the effort. Lastly, the induction of hypoxic stress during the re-training session helped to improve patients' sleep.

Conditions

  • Intermittent Hypoxia
  • Exercise Recovery
  • Intermittent Exercise
  • Rating Exertion Perception
  • Sleep

Interventions

OTHER

Normobaric hypoxia

Normobaric hypoxia (inspired oxygen fraction of 12.9%) applied between-sets recovery periods

OTHER

normoxic condition

Between-sets recovery periods under normoxic condition

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2027-07-31
Completion
2027-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07072975 on ClinicalTrials.gov